CanBas Co Ltd
4575
Company Profile
Business description
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
Contact
2-2-1 Otemachi
Numazu
Shizuoka410-0891
JPNT: +81 559543666
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
14
Stocks News & Analysis
stocks
ASX utility share downgraded as electricity prices fall
Falling electricity prices weigh on earnings outlook for utility provider.
stocks
Chart of the Week: AI market leader is now surprisingly cheap
This AI beneficiary may still be one of the market’s most compelling bargains.
stocks
Weekly earnings wrap: Rio Tinto leads the way
A closer look at the key earnings results from the first week of August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,405.40 | 59.70 | 0.64% |
| CAC 40 | 8,669.30 | 0.00 | 0.00% |
| DAX 40 | 26,126.30 | 76.05 | -0.29% |
| Dow JONES (US) | 54,349.12 | 263.24 | 0.49% |
| FTSE 100 | 10,888.30 | 8.92 | 0.08% |
| HKSE | 25,915.82 | 62.90 | 0.24% |
| NASDAQ | 26,363.44 | 221.55 | -0.83% |
| Nikkei 225 | 66,300.44 | 2,342.91 | 3.66% |
| NZX 50 Index | 13,968.88 | 28.30 | -0.20% |
| S&P 500 | 7,723.55 | 12.97 | -0.17% |
| S&P/ASX 200 | 9,227.80 | 51.30 | 0.56% |
| SSE Composite Index | 3,878.43 | 56.15 | 1.47% |